Navigation Links
Hormone replacement therapy appears to have no effect on risk and severity of rheumatoid arthritis
Date:2/27/2008

Although rheumatoid arthritis (RA) is more predominant in women, the reasons for this are unclear. Many studies have examined the effects of estrogen on the risk and severity of RA, but the results are conflicting and controversial. A new study using data from the Womens Health Initiative (WHI) clinical trials on hormone replacement therapy found that there were no significant differences in the risk of developing RA or the severity of RA between postmenopausal women who were on hormone replacement therapy and those who took placebos. The study was published in the March issue of Arthritis Care & Research (http://www.interscience.wiley.com/journal/arthritiscare).

The WHI randomized controlled trials included over 27,000 postmenopausal women between the ages of 50 and 79 who took estrogen and progestin, estrogen alone or a placebo. Led by Brian Walitt of Washington Hospital Center in Washington, DC, the current study identified women who had RA based on whether they reported having it and were taking prescription medications to treat it. Self-reported information about whether women had RA was collected annually, and they were assessed for disease severity at the beginning of the study and after one year. Measures of self-reported joint pain/stiffness were also collected at that time and participants were asked to rate the severity of their symptoms.

The study is the only placebo-controlled trial to evaluate the effect of hormone replacement therapy on developing RA and the sixth study to evaluate the effects of hormone therapy on how women perceive disease severity. The results showed that there were 105 new cases and 63 existing cases of RA. There were no statistically significant differences on either new RA cases over an average of five to six years or on the severity of RA symptoms after one year. While earlier studies had suggested that hormones had a protective effect against developing RA, they were observational. The current study found no significant protective benefit from hormones in preventing RA.

Although the prevalence of RA in the study was about half of what is found in the general population, this may be due to the tendency of clinical trials to recruit healthier patients and the exclusion of participants taking prednisone, which is used to treat arthritis. Although the WHI methodology has many advantages over prior studies, the sample size for RA was much less than what would be required to observe the effect of hormone replacement therapy on developing RA. However, it is unlikely that larger studies will be carried out, due to the health risks of hormone replacement therapy. Also, the study relied on self-reported information, and even though it tried to minimize overreporting by including only women taking medications for RA, this approach is not as effective as performing chart reviews or physical exams.

The authors conclude that the design of the WHI provided a unique opportunity to examine the effects of PHT [postmenopausal hormone therapy] on RA. Despite the participation of 27,347 women, there was no statistically significant evidence of a difference in the hazard of RA incidence or a difference in RA symptom severity between the PHT and placebo groups.


'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Hormone therapy increases frequency of abnormal mammograms, breast biopsies
2. LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies
3. Hormone refractory prostate cancers more likely to spread to other organs
4. Newly discovered role of thyroid hormone during pregnancy
5. Stress hormone impacts memory, learning in diabetic rodents
6. Moving beyond tamoxifen: Drug discovery and the future of selective hormone receptor modulators
7. Diabetes, Growth Disorders Drive Sales of Pediatric Hormone Drugs
8. Sex Hormones Dont Seem to Affect Prostate Cancer Risk
9. Hormone Therapy Only Helps Some Older Men With Prostate Cancer
10. FDA Warns Against Bio-Identical Hormone Therapy
11. FDA Asserts New Policy to Restrict Womens Access to Bioidentical Hormones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Maryland (PRWEB) , ... January 16, 2017 , ... ... Thibodeau has been appointed Chief Executive Officer of the medical device company, effective ... Vixiar Chairman Robert Storey. “Kevin has a strong track record in medical ...
(Date:1/15/2017)... ... January 15, 2017 , ... Whole Health Supply, LLC is announcing the release of an ... new avenues for purchase. , The 2017 edition has wide jaws that will accommodate ... older boomers as well as diabetics. This handle is reinforced for extra strength when pressing ...
(Date:1/15/2017)... ... January 14, 2017 , ... Wondering where to go ... delivered straight to your door for a romantic, lobster feast in the comfort of ... for Valentine's Day. The dinners will be featured until February 15th, 2017. , ...
(Date:1/14/2017)... , ... January 13, 2017 , ... ... and Soul, incorporating a magnesium-rich Mediterranean diet may lower the risk of type ... Lounge notes that the many health and wellness benefits linked to a Mediterranean ...
(Date:1/13/2017)... ... ... The 18th European Congress: Perspectives in Lung Cancer will be held in ... is expertly designed to meet the educational needs of European oncology clinicians and researchers ... Dr. Giorgio V. Scagliotti, Professor of Oncology at the University of Torino, and organized ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... PUNE, India , January 16, 2017 ... titled, "Vital Signs Monitoring Devices Market by Type and End ... the global vital signs monitoring devices market size was worth ... million by 2022, growing at a CAGR of 5.8% from ... the leading regional market in global vital signs monitoring devices ...
(Date:1/16/2017)... and PUNE, India , January ... new report published by Allied Market Research, titled, "Sterilization ... Analysis and Industry Forecast, 2014-2022," the global sterilization technologies ... from $5,768 million in 2015, growing at a CAGR ... gas sterilization segment dominated the market in 2015, with ...
(Date:1/16/2017)... PORTLAND, Oregon and PUNE, India , January 16, ... Market Research, titled, "Antioxidants Market by Type - Global Opportunity Analysis and Industry ... and is expected to reach $4,531 million by 2022, registering a CAGR of ... accounted for more than one-third share of the global volume in 2015. ... ...
Breaking Medicine Technology: